Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783563 | 0.92 | PRKCI (0.49) | PRKCIKDR | |
| SCHEMBL5871245 | 0.87 | CYP4F2 (0.43) | CYP4F2CYP4A11IDO1BACE1 | |
| SCHEMBL1206636 | 0.85 | CA12 (0.38) | CYP11B1CYP11B2KDRUSP14GPBAR1 | |
| SCHEMBL840465 | 0.85 | GABRA1 (0.45) | ENPP2BACE1 | |
| SCHEMBL11942311 | 0.85 | IDO1 (0.38) | IDO1 | |
| SCHEMBL7174917 | 0.84 | CA2 (0.37) | USP14GPBAR1CYSLTR1BACE1 | |
| SCHEMBL31139306 | 0.83 | IDO1 (0.36) | CYP4F2CYP4A11IDO1BACE1 | |
| SCHEMBL15687564 | 0.83 | IDO1 (0.36) | IDO1USP14BACE1 | |
| SCHEMBL4380251 | 0.83 | ENPP2 (0.43) | MRGPRX4ENPP2IDO1MAOB | |
| SCHEMBL27544251 | 0.83 | IDO1 (0.36) | IDO1USP14BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024199069-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-108473497-B | EP4 antagonists | 卫材R&D 管理有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| CN-108026067-B | 6-amino-quinoline-3-carbonitriles as COT modulators | 吉利德科学公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-0801061-A2 | Leucotrien-B4 derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-15 | — | — | EP | disclosed |
| US-5614634-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5440044-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0477311-A1 | NEW LEUCOTRIENE B 4? DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-04-01 | — | — | EP | disclosed |
| WO-1991014676-A1 | NEW LEUCOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |
| US-4525586-A | Composition and process | THE UPJOHN COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
| US-4420632-A | PROSTAGLANDINS; ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| US-4349689-A | Methano carbacyclin analogs | THE UPJOHN COMPANY (US) | 1982-09-14 | — | — | US | disclosed |
| US-4306075-A | Composition and process | THE UPJOHN COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4306076-A | Inter-phenylene CBA compounds | THE UPJOHN COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | MRGPRX4 32/4885PRSS1 447/4885PRSS2 656/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | MRGPRX4 32/4885PRSS1 447/4885PRSS2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.